Lisata Therapeutics Appoints Jeffrey Farrow to Board of Directors

By Public Technologies
  • Lisata Therapeutics appointed Jeffrey Farrow to its board, effective October 13, 2026.
  • Farrow fills a newly created Class III seat, expanding the board from seven to eight members. He will serve on the Audit Committee.
  • He was chief financial officer of Global Blood Therapeutics from 2016 to 2022, through its acquisition by Pfizer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610141605PRIMZONEFULLFEED9845929) on October 14, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk